Men with end-stage kidney disease and prostate cancer (PCa) are not more likely to die from the malignancy if they receive a kidney transplant (KT) compared with undergoing dialysis, data presented at the virtual 2021 American Transplant Congress suggest.
Using Surveillance, Epidemiology and End Results (SEER)-Medicare registry 2004-2015 data, Nagaraju Sarabu, MD, of University Hospital Cleveland Medical Center in Cleveland, Ohio, and colleagues conducted a retrospective study of 1959 men diagnosed with PCa following a diagnosis of end-stage kidney disease: 1478 on dialysis and 481 with a functioning kidney transplant.
In adjusted analyses, KT recipients had a significant 45% reduced risk for overall mortality compared with dialysis patients, but the groups did not differ significantly with regard to PCa-specific mortality, Dr Sarabu’s team reported.
Compared with men on dialysis, KT recipients were more likely to present with local disease (85.9% vs 71.8%) and less likely to present with distant disease (4.0% vs 14.5%), according to the investigators.
Surgical or radiation treatment for PCa was not associated with improved PCa-specific survival.
The findings support a recent recommendation by an American Society of Transplantation expert panel that KT candidates with local or regional PCa do not need to wait additional time for a kidney transplant due to the cancer.
Patient characteristics associated with worse PCa-specific survival included regional and distant cancer stage at presentation, Gleason score greater than 8, and PSA level above 20 ng/mL.
Sarabu N, Dong W, Koroukian SM. Prostate cancer mortality is not worse among kidney transplant recipients compared to dialysis patients. Presented at: ATC 2021, held from June 4-9. Abstract 1279.
This article originally appeared on Renal and Urology News